Hormone Replacement Therapy for Women with an Intact Uterus
For postmenopausal women with an intact uterus, you must prescribe combined estrogen-progestogen therapy—never estrogen alone—to prevent endometrial hyperplasia and cancer. 1
Essential Treatment Framework
Mandatory Progestogen Protection
A progestogen is absolutely required in all women with a uterus receiving systemic estrogen therapy. This is non-negotiable for endometrial protection 1. Unopposed estrogen at any dose and duration (1-3 years) significantly increases the risk of endometrial hyperplasia 2.
Two Regimen Options
You have two evidence-based approaches:
1. Combined Continuous Regimen (Preferred for most women)
- Both estrogen and progestogen administered daily without interruption
- Best for women more than 1-2 years post-menopause
- Lower rates of breakthrough bleeding once established 1
2. Combined Sequential Regimen
- Estrogen for 20-25 days with progestogen added for 12-15 days each month
- Preferred for recently menopausal women who are prone to breakthrough bleeding during the first 1-2 years of therapy 1
Estrogen Selection: Route Matters
Transdermal estrogen (patches, gels, sprays) is preferable to oral estrogen for most women, particularly those with cardiovascular risk factors 1.
When to Strongly Favor Transdermal:
- VTE risk or history
- Hypertension
- Hypertriglyceridemia
- Obesity or metabolic syndrome
- Diabetes
- History of gallbladder disease 1
Why transdermal is superior: It bypasses first-pass hepatic metabolism, avoiding the procoagulant effects, increases in inflammatory markers (C-reactive protein), triglycerides, and binding globulins that occur with oral estrogen 1.
Oral Estrogen Options:
- Micronized estradiol or conjugated estrogens remain acceptable if no contraindications exist
- Results in 5-fold higher estrone and 10-20-fold higher estrone sulfate levels compared to transdermal, though clinical significance remains unclear 1
Progestogen Selection and Dosing
Minimum effective doses for endometrial protection:
- Norethisterone acetate (NETA): ≥1 mg daily
- Medroxyprogesterone acetate (MPA): ≥1.5 mg daily 2
These doses in continuous combination with low-dose estrogen show no significant difference from placebo in endometrial hyperplasia risk 2.
Available Progestogen Routes:
- Oral (most studied)
- Transdermal patch
- Vaginal
- Intrauterine (levonorgestrel IUD) 1
Caveat on levonorgestrel IUD: While it minimizes systemic absorption, one observational study reported higher breast cancer incidence, though this requires further validation 1.
Critical Safety Considerations
Breast Cancer Risk Varies by Regimen:
- Estrogen-only therapy (hysterectomized women): Decreased breast cancer risk (8 fewer per 10,000 woman-years) 3
- Estrogen plus progestin: Increased breast cancer risk (8 more per 10,000 woman-years) 3
- Progestogens structurally related to testosterone show higher risk (RR 3.35) 4
Other Established Risks with Combined Therapy:
- Stroke: 9 more per 10,000 woman-years
- VTE: 21 more per 10,000 woman-years (DVT + PE combined)
- Dementia (if started age >65): 22 more per 10,000 woman-years
- Gallbladder disease: 20 more per 10,000 woman-years 3
Benefits:
- Fracture reduction: 46 fewer per 10,000 woman-years 3
- Effective vasomotor symptom relief
- Endometrial cancer protection with adequate progestogen 4
Practical Implementation
Start with the lowest effective dose and use FDA-approved preparations—never custom-compounded hormones 1. Custom-compounded therapies lack FDA oversight and have no clinical trial data documenting efficacy or safety for endometrial protection 1.
Initiate therapy close to menopause (age <60 or within 10 years of menopause) for optimal benefit-risk profile 5. Starting HT in older women or those remote from menopause increases cardiovascular and dementia risks 3.
Review therapy regularly and use at the lowest effective dose for the shortest duration needed 2, 5.
Common Pitfall to Avoid
Never prescribe systemic estrogen alone to a woman with an intact uterus, regardless of dose or formulation. Even low-dose vaginal estrogen preparations delivering systemic levels (high-dose creams, 50-100 µg vaginal rings) require concomitant progestogen 1. This includes estradiol acetate vaginal rings and 1-2g vaginal creams containing estradiol or conjugated estrogens 1.